Antibody Response Dynamics as an Early Predictor of Clinical Outcome in Severe Fever With Thrombocytopenia Syndrome (SFTS): A Retrospective Cohort Study for Prognostic Model Development
Journal of Medical Virology · 2026
DOI: 10.1002/jmv.70830 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Rong Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Virology Testing, Disease Prevention and Control Center of Ningbo City, Ningbo, Zhejiang, China. Hauptthemen laut MEDLINE: Severe Fever with Thrombocytopenia Syndrome, Antibodies, Viral, Antibody Formation. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
This study investigated the humoral immune response dynamics in patients with severe fever with thrombocytopenia syndrome (SFTS) to evaluate their prognostic value and construct an early warning model. A retrospective cohort of 36 laboratory‐confirmed SFTS patients with ≥ 4 serial antibody measurements out of 153 patients recruited in the study were analyzed. Patients were categorized by outcome into mild, severe, and fatal groups. The results showed that, the fatal group was older, had more comorbidities, and showed no antibody seroconversion during follow‐up, along with a significantly higher day‐7 viral load. Early seroconversion (IgM/IgG ≤ 7 days post‐admission) was associated with shorter recovery time and higher survival compared to delayed seroconversion (> 7 days) or antibody‐deficient status. Antibody seroconversion time was strongly positively correlated with recovery time. Advanced age (≥ 70 years) was a significant risk factor for severe/fatal outcomes and was linked to delayed or absent seroconversion. A synergistic interaction was found between age and day‐7 antibody status. A simple early warning model combining age and day‐7 antibody status demonstrated good predictive performance with an AUC of 0.83. The findings indicate that antibody response timing and advanced age are key prognostic factors in SFTS. The proposed model shows promise for early identification of high‐risk patients in resource‐limited settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Virology Testing, Disease Prevention and Control Center of Ningbo City, Ningbo, Zhejiang, China.
- Department of Infectious Disease Prevention and Control, Disease Prevention and Control Center of Daishan County, Zhoushan, Zhejiang, China.
- Department of infection, Zhoushan Hospital Affiliated to Wenzhou Medical University, Zhoushan, Zhejiang, China.
- Department of Chronic Non-Communicable Disease Prevention and Control, Disease Prevention and Control Center of Huai'an City, Huaian, Jiangsu, China.
- Changzhou Maternity and Child Health Care Hospital, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, China.
- Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.
ORCID-Profile: Zhilei Mao
Förderung
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Wang, R., Tan, Q., Li, Q., Li, S., Miao, D., & Mao, Z. (2026). Antibody Response Dynamics as an Early Predictor of Clinical Outcome in Severe Fever With Thrombocytopenia Syndrome (SFTS): A Retrospective Cohort Study for Prognostic Model Development. Journal of Medical Virology. https://doi.org/10.1002/jmv.70830
Vancouver
Wang R, Tan Q, Li Q, Li S, Miao D, Mao Z. Antibody Response Dynamics as an Early Predictor of Clinical Outcome in Severe Fever With Thrombocytopenia Syndrome (SFTS): A Retrospective Cohort Study for Prognostic Model Development. Journal of Medical Virology. 2026. doi:10.1002/jmv.70830
BibTeX
@article{Wang2026,
author = {Wang, Rong and Tan, Qilong and Li, Qiongyan and Li, Shibo and Miao, Dandan and Mao, Zhilei},
title = {Antibody Response Dynamics as an Early Predictor of Clinical Outcome in Severe Fever With Thrombocytopenia Syndrome (SFTS): A Retrospective Cohort Study for Prognostic Model Development},
journal = {Journal of Medical Virology},
year = {2026},
doi = {10.1002/jmv.70830}
}
EUVIMED